Build a flexible access portfolio, not a budget that depends on one promotion, one pharmacy or one regulatory interpretation. Our recommendation is to complete route screening before price scoring, model patient and clinic expenditure separately, and make transition readiness an approval condition.
The following are planning anchors and scenarios—not forecasts of prices, approvals, patient demand or clinical results.
Sources cited on this page
See the section’s source register for the research context.
Section sources →